vTv Therapeutics Inc
Change company Symbol lookup
Select an option...
VTVT vTv Therapeutics Inc
BUGDF Bumrungrad Hospital PCL
ORCL Oracle Corp
OPTT Ocean Power Technologies Inc
SPEYF Spey Resources Corp
BCTX Briacell Therapeutics Corp
JAZZ Jazz Pharmaceuticals PLC
KRT Karat Packaging Inc
REMRF Red Moon Resources Inc
ARR ARMOUR Residential REIT Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Price
Delayed
$2.54
Day's Change
0.1786 (7.57%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.50
Volume
(Heavy Day)

Today's volume of 16,501,176 shares is on pace to be much greater than VTVT's 10-day average volume of 1,787,956 shares.

16,501,176

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.